Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 78, Issue 6, Pages 1149-+Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2017.09.076
Keywords
immune response; Janus kinase inhibitor; pneumococcal vaccine; T cell; tetanus toxoid; tofacitinib
Categories
Funding
- Pfizer Inc.
Ask authors/readers for more resources
Background: Psoriasis is often treated with immunomodulatory therapies that can affect the immune response to common antigens. Tofacitinib is an oral Janus kinase inhibitor. Objective: To characterize the effect of long-term exposure to tofacitinib 10 mg twice daily on T-cell function in psoriasis patients. Methods: Patients completing at least 3 months' continuous treatment with tofacitinib 10 mg twice daily were vaccinated with T-cell-dependent vaccines (monovalent tetanus toxoid and 13-valent pneumococcal conjugate [PCV-13]). Patients were assessed at baseline (before vaccination) and then again 4 weeks after vaccination. For PCV-13, we evaluated serotype-specific, opsonophagocytic antibody responses, and for tetanus toxoid, we evaluated humoral responses. Results: Among 60 patients who completed the study, the geometric mean fold rise from baseline for the 13 PCV serotypes at 4 weeks postvaccination varied from 8.3 (serotype 3) to 101.9 (serotype 6A). Similar results were observed for patients with and without lymphopenia at baseline. For tetanus toxoid, 51 (88%) patients had >= 2-fold and 35 (60%) patients had >= 4-fold rise in antibody concentration. Limitations: There was no placebo control. Conclusion: Most psoriasis patients who receive tofacitinib can mount satisfactory T-cell-dependent responses to PCV-13 and tetanus vaccines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available